Publication | Closed Access

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Dose-ranging TrialsPharmacologyHyperlipidemiaPharmacotherapyDyslipidemiaLipoprotein MetabolismAntisense TherapyMedicineAtherosclerosisEpidemiology